Author Archives: april@madhedgefundtrader.com

The Laziness Premium

I spent last Tuesday afternoon on a call with a fund manager who runs $3 billion and couldn’t explain to me why his team was avoiding GSK (GSK). Something about HIV competition and patent cliffs and the usual hand-waving you get from analysts who haven’t actually dug into the numbers. I let him finish his […]

European Tech Bows Out

People ask me, well, why the Europeans never developed a thriving and meaningful tech sector. I’ll give you a recent example of why they never will, so just keep reading along. The Netherlands’ stealing of China-owned chip company Nexperia has to be one of the biggest own goals in recent tech history, and highlights the […]

The Biotech Graveyard Has A Survivor

I spent last weekend with an old friend from my Goldman days, and watching him care for his mother, who’s deep into Alzheimer’s, reminded me why I’ve been tracking Biogen (BIIB) so closely. The disease is brutal, and for the longest time, the investment thesis around Alzheimer’s therapeutics felt more like charity than capitalism. But […]